Dexmedetomidine for Sedation Complication (CLASS-D Trial)

"In order to be considered for this medical trial, applicants must have experienced sedation-related issues and fall within the 18-40 age bracket. This study is seeking approximately 20 participants."

"Currently, 23 Phase 3 trials for Dexmedetomidine are active across 204 clinical sites worldwide. Most of these studies originate in Karachi, Sindh province alone."

"Dexmedetomidine is the typical intervention for this malady, but it may also be beneficial in cases of ventilation distress, mechanical obstruction, cyclic vomiting syndrome and intubations."

"The primary outcome of this trial, to be evaluated up to 3 months post-consent, is the divergence between EEG slow wave duration from a placebo and in-phase stimulation. Secondary effects being measured include the sensitivity threshold for thermal stimuli when comparing sham and in-phase treatments as well as anti-phase and in-phase therapies; changes in nocturnal slow wave activity will also be assessed against levels prior to study sessions."

"At this moment in time, participation for the aforementioned study is not being actively sought. Originally posted on January 20th 2021 and last updated November 29th 2022, if you are interested in other trials there exist 150 sedation complication studies and 108 Dexmedetomidine clinicals recruiting patients currently."

"The minimum age requirement for entry into this trial is 18 years old, while the maximum allowable age is 40."

"This clinical trial is now closed for recruitment and has been since November 29th, 2022. If you are seeking other medical studies to participate in, there currently 150 experiments searching for patients dealing with sedation complications and 108 trials using Dexmedetomidine that are actively recruiting participants."